The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.

Order Print Edition


This publication discusses the use of Revlimid (lenalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
The Understanding SARCLISA® (isatuximab-irfc) booklet discusses a novel anti-CD38 monoclonal antibody that is approved for patients with relapsed and…
The IMF’s Understanding Stem Cell Transplant in Myeloma publication is intended for myeloma patients in the United States who are in discussions with…
Talvey is indicated for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior lines of therapy.
Tecvayli™ (teclistmab-cqyv) is the first in a drug class of bispecific antibodies approved by the FDA to treat myeloma.

We Thank Our Sponsors:
BMS, GSK, Janssen Oncology, Sanofi, and Takeda Oncology.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.